Group 1 - The core idea of the news is that New Oriental, led by founder Yu Minhong, plans to establish an e-commerce training school this year to enhance the skills of e-commerce operators and live streamers in China [2][3] - The initiative is driven by the increasing emphasis from local authorities on e-commerce training, with a focus on collaborative learning rather than isolated efforts [2] - The training school will be located in Beijing, a hub for talent, allowing for the recruitment of experienced instructors to provide quality education [2] Group 2 - Yu Minhong had previously expressed the idea of creating an e-commerce academy during a live stream last year, highlighting the need for cultural training for e-commerce live streamers [3] - The goal of the training is not solely for profit but to elevate the overall quality of Chinese live streamers [3] - Yu Minhong intends to personally teach at the academy and will also invite renowned streamers to participate in the training [3]

Market Performance - The three major U.S. stock indices closed higher, with the Dow Jones up 0.04%, the Nasdaq up 0.9%, and the S&P 500 up 0.47% [1] - Major technology stocks saw significant gains, with Oracle rising over 9%, Microsoft and Broadcom up over 3%, and Nvidia and Meta up over 2% [1] Sector Performance - Cryptocurrency mining companies, precious metals, and non-ferrous metals led the gains, with Vista Gold up over 14%, Hut 8 up over 7%, and Pan American Silver up over 6% [1] - Other notable performers included Alcoa and Royal Gold, both rising over 5%, and Southern Copper up over 4% [1] - Retail and insurance brokerage sectors faced declines, with Macy's and Kohl's both down over 5%, and the American Reinsurance Group down over 2% [1] Chinese Stocks - The Nasdaq Golden Dragon China Index rose 0.12%, with notable gains in Chinese concept stocks such as Kingsoft Cloud, Pony.ai, and JinkoSolar, which rose up to 3.79% [1] - Other gainers included Zai Lab up 2.44%, Huazhu up 1.66%, while companies like Yum China, XPeng, Ctrip, Bilibili, NIO, Li Auto, and New Oriental experienced declines, with New Oriental down 4.24% [1]

Market Overview - On February 9, US stock indices opened lower, with the Nasdaq down 0.37%, the Dow Jones down 0.21%, and the S&P 500 down 0.26% [1] - The Nasdaq China Golden Dragon Index fell by 0.7%, with notable declines in several Chinese concept stocks, including Li Auto, Bilibili, New Oriental, and NIO, which all dropped over 3% [2] Chinese Concept Stocks - Li Auto decreased by 3.80% to $18.250 - Bilibili and New Oriental both fell by 3.30%, with prices at $30.490 and $60.650 respectively - Other significant declines included Ctrip Group down 1.95% to $58.240, Baidu down 1.64% to $143.540, and JD Group down 1.10% to $27.760 [3] Large Tech Stocks - Large technology stocks showed mixed performance, with SanDisk dropping over 4% and AMD down nearly 2%, while Oracle saw an increase of nearly 5% [4] - SanDisk fell by 4.55% to $570.725, while Oracle rose by 4.93% to $149.855 [5]

智通财经APP获悉，香港联交所最新资料显示，2月3日，第一北京投资有限公司减持新东方- S(09901)144.12万股，每股作价49.0174港元，总金额约为7064.39万港元。减持后最新持股数目约为1.88 亿股，最新持股比例为10.96%。 ...

香港联交所最新资料显示，2月3日，第一北京投资有限公司减持新东方-S(09901)144.12万股，每股作价 49.0174港元，总金额约为7064.39万港元。减持后最新持股数目约为1.88亿股，最新持股比例为 10.96%。 ...

Investment Rating - The report indicates a positive outlook for the pharmaceutical sector, particularly for innovative drugs and companies expected to reach profitability in 2025 [1][9][15]. Core Insights - The innovative drug sector is anticipated to see significant growth due to the commercialization of core products and contributions from business development (BD) revenues, with companies like BeiGene, Innovent Biologics, and others expected to achieve profitability [1][9]. - The Pharma sub-sector is projected to experience a revenue growth rate of 15-20% in 2025, with notable companies such as Hansoh Pharmaceutical and China Biologic Products leading this growth [2][10]. - The CXO sector is also expected to report strong performance, with companies like WuXi AppTec forecasting substantial revenue and profit increases [3][11]. - The medical services sector is currently valued at historical lows, with a projected revenue growth of 13% for Genscript Biotech, highlighting the importance of monitoring industry changes [4][12]. Summary by Sections Innovative Drugs - Companies expected to achieve profitability in 2025 include BeiGene, Innovent Biologics, and others, driven by increased commercialization and BD revenues [1][9]. Pharma - Revenue growth of 15-20% is expected for leading companies such as Hansoh Pharmaceutical and China Biologic Products, with a significant boost anticipated for 3SBio due to a major BD deal with Pfizer [2][10]. CXO - WuXi AppTec is projected to achieve approximately 454.56 billion RMB in revenue, reflecting a year-on-year growth of about 15.84%, with adjusted net profits expected to rise significantly [3][11]. Medical Services - Genscript Biotech is expected to see a revenue increase of 13% in 2025, emphasizing the need to focus on overseas business expansion and AI integration in traditional medicine [4][12].

Investment Rating - The report maintains a positive outlook on the pharmaceutical sector, indicating an "Overweight" rating for the industry, suggesting it will outperform the overall market [1]. Core Insights - The report highlights that the commercialization of innovative drugs, combined with licensing income, is expected to lead to profitability for several companies in 2025, including BeiGene, Innovent Biologics, and others [1][9]. - The Pharma sub-sector is projected to achieve a revenue growth rate of 15-20% in 2025 for companies like Hansoh Pharmaceutical and China Biologic Products, with a significant revenue increase expected for 3SBio due to a major business development deal with Pfizer [2][10]. - The CXO sector is also expected to show strong performance, with companies like WuXi AppTec forecasting a revenue increase of approximately 15.84% and a net profit growth of about 102.65% in 2025 [3][11]. - In the medical services sector, the report notes that valuations are at historical lows, with a projected revenue growth of 13% for GuoShengTang in 2025, emphasizing the importance of overseas business expansion and AI integration in traditional Chinese medicine [4][12]. Summary by Sections Innovative Drugs - The report anticipates that several innovative drug companies will reach profitability in 2025 due to increased commercialization and business development income [9][15]. Pharma - The Pharma sub-sector is expected to see a revenue growth of 15-20% in 2025 for key players, with 3SBio projected to achieve over 100% growth due to a significant partnership with Pfizer [2][10]. CXO - WuXi AppTec is expected to report a revenue of approximately 454.56 billion RMB in 2025, with a net profit growth of around 102.65% [3][11]. Medical Services - GuoShengTang is projected to have a revenue growth of 13% in 2025, with a focus on overseas acquisitions and AI applications in traditional medicine [4][12].

Group 1: New Oriental (EDU) - New Oriental's FY26Q2 net revenue increased by 14.7% year-on-year to $1.191 billion, slightly exceeding the previous guidance of $1.132 to $1.163 billion[9] - Operating profit reached $66.3 million, up 244.4% year-on-year, while Non-GAAP operating profit rose by 206.9% to $89.13 million[9] - The company adjusted its FY26 revenue guidance to between $5.292 billion and $5.49 billion, reflecting a year-on-year growth of 8% to 12%[12] Group 2: Financial Metrics - The target price for New Oriental is set at $78.00, representing a potential upside of 24.3% from the current price of $62.8[6] - The company's EPS for FY26 is projected to be $0.31, an increase of 3% from the previous estimate of $0.30[2] - The net profit margin improved by 0.7 percentage points to 3.8%, while Non-GAAP net profit margin increased by 1.9 percentage points to 6.1%[10] Group 3: Business Performance - New business revenue grew by 21.6% year-on-year, with non-academic tutoring registrations reaching 1.058 million, a 6.4% increase[11] - The number of active paid users for the smart learning system and devices reached 352,000, up 34.8% year-on-year[11] - The company operates 1,379 learning centers and schools, a significant increase from 1,189 in FY25Q2[11] Group 4: Market Outlook - The company expects FY26Q3 net revenue to be between $1.313 billion and $1.349 billion, indicating a year-on-year growth of 11% to 14%[12] - The overall positive performance is attributed to the recovery of new business growth and effective cost management, leading to improved profit margins[10]

Core Viewpoint - The Nasdaq Golden Dragon China Index saw an initial increase of 1.21%, indicating positive market sentiment towards Chinese stocks listed in the U.S. [1] Company Performance - NIO experienced a significant rise of 7.4% - Miniso increased by 5.4% - Yum China rose by 3.4% - Li Auto gained 2.8% - ZTO Express, Zai Lab, Bilibili, Baidu, and Kingsoft Cloud all saw increases of over 2% - Alibaba had a modest increase of 0.7% - Pony.ai declined by 1.2% - New Oriental fell by 2.8% [1] ETF Performance - KWEB ETF rose by 1.14% - CQQQ ETF increased by 0.7% - ASHR ETF decreased by 0.1% - ASHS ETF fell by 1.3% [1]

来源：中国网 2月3日，2025年"中国大学生自强之星"活动分享会在北京交通大学科学会堂举行。本次活动由共青团中 央基层建设部指导，中国青年报社、中国青少年发展基金会主办，新东方教育科技集团协办，聚焦立德 树人根本任务，深入挖掘在爱国奉献、道德弘扬、科技创新、自主创业、志愿公益、身残志坚、自立自 强等方面事迹突出的新时代大学生先进典型，树立青年榜样。本年度共产生1000名"中国大学生自强之 星"个人及100个"中国大学生自强之星科创团体"。 "中国大学生自强之星"评选活动于2007年启动，新东方先后共出资1亿元，在全国范围内寻访青年榜 样。十八年来，活动共产生1.5万余名"中国大学生自强之星"。值得一提的是，自2024年度首次增设"科 创团体"类别以来，该类别累计获奖团体已达200个。他们与个人获奖者共同构建起更为立体、多元的青 年榜样群像，展现出新时代大学生在科技创新与团队协作中的蓬勃朝气与担当精神。 分享会伊始，北京交通大学党委常委、副校长李国岫在致辞中指出，自强的学子"用很真实的奋斗诠释 着新时代青年的优秀"，他们将自信、自立、自强内化为人生信条，将个人奋斗融入了时代洪流。他强 调，学校通过"将外在的资 ...